CA3004587A1 - Use of proteasome inhibitors to treat ocular disorders - Google Patents

Use of proteasome inhibitors to treat ocular disorders Download PDF

Info

Publication number
CA3004587A1
CA3004587A1 CA3004587A CA3004587A CA3004587A1 CA 3004587 A1 CA3004587 A1 CA 3004587A1 CA 3004587 A CA3004587 A CA 3004587A CA 3004587 A CA3004587 A CA 3004587A CA 3004587 A1 CA3004587 A1 CA 3004587A1
Authority
CA
Canada
Prior art keywords
group
eye
composition
ocular
proteasome inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3004587A
Other languages
English (en)
French (fr)
Inventor
Rick Coulon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Accuitis Pharmaceuticals Inc
Original Assignee
Accuitis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accuitis Pharmaceuticals Inc filed Critical Accuitis Pharmaceuticals Inc
Publication of CA3004587A1 publication Critical patent/CA3004587A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3004587A 2015-11-06 2016-10-24 Use of proteasome inhibitors to treat ocular disorders Abandoned CA3004587A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562251937P 2015-11-06 2015-11-06
US62/251,937 2015-11-06
PCT/US2016/058402 WO2017078953A1 (en) 2015-11-06 2016-10-24 Use of proteasome inhibitors to treat ocular disorders

Publications (1)

Publication Number Publication Date
CA3004587A1 true CA3004587A1 (en) 2017-05-11

Family

ID=58662653

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3004587A Abandoned CA3004587A1 (en) 2015-11-06 2016-10-24 Use of proteasome inhibitors to treat ocular disorders

Country Status (8)

Country Link
US (1) US20180325854A1 (enExample)
EP (1) EP3370709A4 (enExample)
JP (1) JP2018533629A (enExample)
CN (1) CN108883081A (enExample)
AU (1) AU2016349833A1 (enExample)
CA (1) CA3004587A1 (enExample)
IL (1) IL259153A (enExample)
WO (1) WO2017078953A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110840860A (zh) * 2019-11-22 2020-02-28 国家纳米科学中心 一种纳米药物及其制备方法和应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019149648A1 (en) 2018-01-30 2019-08-08 Universiteit Gent Compositions for use to treat cataract
WO2020123362A1 (en) * 2018-12-10 2020-06-18 EternaTear, Inc. Ophthalmic formulations providing durable ocular lubrication
US12594351B2 (en) * 2021-08-04 2026-04-07 Harrow Ip Llc Methods for increasing shelf-life of ophthalmic pharmaceutical compositions
US11679078B1 (en) 2022-03-08 2023-06-20 EternaTear, Inc. Ophthalmic formulations and related methods
US11471475B1 (en) 2022-03-08 2022-10-18 Ralph P. Stone Ophthalmic suspension vehicles and related methods for pharmaceutical ingredient delivery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770115A (en) * 1996-04-19 1998-06-23 Ppg Industries, Inc. Photochromic naphthopyran compositions of improved fatigue resistance
DK1098649T3 (da) * 1998-04-02 2004-10-04 Novartis Ag Fremgangsmåde til stabilisering af farmaceutiske sammensætninger med speciel anvendelse af antioxidant
CN103230394B (zh) * 2004-12-03 2016-04-20 达纳-法伯癌症研究公司 治疗肿瘤性疾病的化合物及其用途
AU2006251655B2 (en) * 2005-05-20 2012-10-11 Jack Arbiser Proteasome inhibitors and uses thereof
US20090258041A1 (en) * 2005-10-24 2009-10-15 Sebastien Mongiat Protection of Oxidizable Agents
US20090270419A1 (en) * 2006-09-15 2009-10-29 Janine Arts Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors
WO2008042454A1 (en) * 2006-09-29 2008-04-10 Johnson & Johnson Vision Care, Inc. Methods and ophthalmic devices used in the treatment of ocular allergies
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
CN103566049B (zh) * 2012-08-08 2017-08-04 浙江医药股份有限公司新昌制药厂 用于提高眼睛中视黄斑色素密度并预防或治疗年龄相关性视黄斑衰退症的组合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110840860A (zh) * 2019-11-22 2020-02-28 国家纳米科学中心 一种纳米药物及其制备方法和应用
CN110840860B (zh) * 2019-11-22 2021-12-31 国家纳米科学中心 一种纳米药物及其制备方法和应用

Also Published As

Publication number Publication date
JP2018533629A (ja) 2018-11-15
EP3370709A4 (en) 2019-12-18
CN108883081A (zh) 2018-11-23
EP3370709A1 (en) 2018-09-12
IL259153A (en) 2018-06-28
US20180325854A1 (en) 2018-11-15
WO2017078953A1 (en) 2017-05-11
AU2016349833A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
WO2017078953A1 (en) Use of proteasome inhibitors to treat ocular disorders
AU2015257651B2 (en) Compounds for treating ophthalmic diseases and disorders
CA2928969C (en) Compositions and methods for ophthalmic and/or other applications
ES2367804T3 (es) Implantes intraoculares de agonistas del receptor alfa-2 adrenergico para prevenir o reducir las oclusiones vasculares oculares.
ES2326550T3 (es) Uso de un macrolido para restablecer la sensacion corneal.
CA2978874C (en) Ocular formulations comprising a glycosaminoglycan and an anesthetic
US20080125406A1 (en) Method for Treating Primary and Secondary Forms of Glaucoma
Hwang et al. A comparative study of topical mitomycin C, cyclosporine, and bevacizumab after primary pterygium surgery
CN1753683A (zh) 预防和治疗不良眼部病症的眼用制剂
TW201630614A (zh) 無刺激性眼用聚乙烯吡咯啶酮-碘組成物
WO2014066653A1 (en) Ketorolac-containing sustained release intraocular drug delivery systems
AU777655B2 (en) Ophthalmic histamine compositions and uses thereof
US20210085696A1 (en) Formulations comprising chelators, permeation enhancers and hydroxyethyl cellulose for treating ophthalmic disorders
KR20240046311A (ko) 수술 후 안구 염증성 병태를 억제시키기 위한 전방내용의, 항―염증성 및 산동성 용액
US10350223B2 (en) Compositions and methods for treating ocular diseases
Bagnis et al. Antiglaucoma drugs: The role of preservative-free formulations
Pathengay et al. Acute postoperative endophthalmitis following cataract surgery: a review
CN101347438A (zh) 一种减缓眼部新生血管生成的药物
WO2012047893A2 (en) Use of rifazil and analogues thereof to treat ocular disorders
Pérez-Sarriegui et al. Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant
Szaflik et al. Guidelines for perioperative care in cataract surgery in Poland
WO2025090106A1 (en) Compositions and methods for treating neural degeneration in glaucoma and related conditions
US20230064711A1 (en) Compositions, kits and methods for enhancing therapeutic compliance
CN1802151A (zh) 用于治疗病理性眼内血管生成的非甾体类抗炎药制剂
HK40092417A (en) Compounds for treating ophthalmic diseases and disorders

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220426